3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Melanoma
28
Carcinoma, Non-Small-Cell Lung
28
Neoplasm Metastasis
23
Colorectal Neoplasms
19
Carcinoma, Hepatocellular
19
Triple Negative Breast Neoplasms
16
Pancreatic Neoplasms
15
Neoplasms
15
Stomach Neoplasms
13
Squamous Cell Carcinoma of Head and Neck
13
Nasopharyngeal Carcinoma
13
Carcinoma, Renal Cell
13
Uterine Cervical Neoplasms
10
Rectal Neoplasms
10
Lymphoma
8
Sarcoma
7
Esophageal Squamous Cell Carcinoma
7
Esophageal Neoplasms
7
Recurrence
6
Lymphoma, Extranodal NK-T-Cell
6
Lung Neoplasms
6
Locally Advanced Rectal Cancer
6
Breast Neoplasms
6
Advanced Solid Tumor
6
Ovarian Neoplasms
5
Glioblastoma
5
Endometrial Neoplasms
5
Cholangiocarcinoma
5
Small Cell Lung Carcinoma
4
Nasopharyngeal Neoplasms
4
Interventions
Amifostine
19
Cisplatin
15
Radiotherapy
13
Etoposide
10
Cyclophosphamide
9
Carboplatin
8
Paclitaxel
7
Filgrastim
7
Drug Therapy
5
Cytarabine
5
apatinib
4
sodium thiosulfate
3
Methylprednisolone
3
Methotrexate
3
Gemcitabine
3
Docetaxel
3
sargramostim
2
pegfilgrastim
2
etoposide phosphate
2
camrelizumab
2
Vincristine
2
Pyridoxine
2
Peripheral Blood Stem Cell Transplantation
2
Nivolumab
2
Mitoxantrone
2
Melphalan
2
Irinotecan
2
Ifosfamide
2
Fibroblast Growth Factor 7
2
Epoetin Alfa
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Drug-Related Side Effects and Adverse Reactions
×
spartalizumab
×
Clear all
NCT06302062
2024-12-03
TAL-T
Guangzhou FineImmune Biotechnology Co., LTD.
Phase 1
Recruiting
23 enrolled